L’introduzione del vaccino anti-HPV bivalente adiuvato con AS04 nelle regioni italiane: impatto economico ed effetti sulla salute delle donne

Cavallo, Maria Caterina; Cipriani, Filippo; Gerzeli, Simone; Demarteau, Nadia; Marocco, Alessia; Bamfi, Francesco

doi:10.7175/fe.v9i1s.998

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sono stati utilizzati dati specifici relativi a: -demografia; la dimensione delle coorti da vaccinare è tratta dai dati Demo Istat [41] aggiornati per popolazione residente al 1 gennaio 2011 (vedi Tabella III delle schede regionali); -copertura dello screening; i dati sul ricorso allo screening sono tratti dal Sistema di Sorveglianza PASSI [16] (vedi Tabella I delle schede regionali); -costi degli interventi; i costi dei trattamenti per singola regione sono tratti da Cavallo e colleghi [42], (vedi Tabella IV delle schede regionali).…”

Section: Input Inseriti Nel Gcmunclassified

HPV vaccination and allocative efficiency: regional analysis of the costs and benefits with the bivalent AS04-adjuvanted vaccine, from the perspective of public health, for the prevention of cervical cancer and its pre-cancerous lesions

Bonanni

Panatto

Dirodi

et al. 2012

View full text Add to dashboard Cite

ciare la strategia di vaccinazione alla politica di prevenzione secondaria. Come dimostrato dagli studi finora pubblicati, tale strategia congiunta è la più efficace nella prevenzione delle patologie legate all'infezione da HPV INTRODUZIONEAttraverso le decisioni sull'opportunità di introdurre la vaccinazione anti-HPV, la sanità pubblica ha già definito l'importanza di asso- Corresponding authorRoberto Gasparini gasparini@unige.it DisclosureIl presente supplemento è stato realizzato con il finanziamento integrale di GlaxoSmithKline Spa ABSTRACT Introduction: by means of the decisions on whether to introduce the HPV vaccination, Public Health has already established the importance of associating the vaccination strategy to the policy of secondary prevention. The screening + vaccination strategy is more effective than the two methods taken individually. In support of this combined strategy and in order to make available per each region concrete elements for their regional planning, an assessment has been made, which also takes into account the effect of cross-protection regarding high-risk strains not contained in both vaccines, bivalent and quadrivalent, and more frequently responsible for pre-cancerous lesions and cervical cancer (CCU). This analysis evaluates the costs and benefits of screening + vaccination strategy in a 12-year-old female cohort. Furthermore, the paper provides results that may be useful to assess the opportunity to extend the vaccination to a second cohort of 24-25-year-old women. The analysis is preceded by a brief summary of CCU epidemiology available data, public health policies that give precise guidelines for vaccination strategies and analytical tools suitable to support public policy makers to efficiently allocate resources. Methods: two different models were used for two regional analyses.The vaccines may have different sustained-and crossprotection levels against non-vaccine oncogenic HPV-types. In the first analysis, a prevalence-based model estimated the potential net difference in HPV-related lesions (abnormal pap smear, cervical intraepithelial neoplasia (CIN), cervical cancer (CC) and genital warts (GW)) and associated costs generated by the two vaccines. Vaccine efficacy rates were based on published data for each vaccine. Lifetime vaccine efficacy was assumed. Results are reported over one year after reaching a steady state. Incidence and treatment costs were obtained from Italian and European sources. We also performed a cost-effectiveness analysis with a Markov model for each Italian region, previously described and successfully adapted to the national scenario. The analysis compares the HPV vaccination of a single cohort (12-year-old females) with a multiple cohort (12-+ 25-year-old girls). Resource use was based on a standard therapeutic path applied to all regions. However we quantified the impact of the so-called "decentralization progress" by collecting regional data on: pap test coverage, tariffs for treatments, and cost of the vaccination course. Results: the results...

show abstract

Section: Input Inseriti Nel Gcmunclassified

HPV vaccination and allocative efficiency: regional analysis of the costs and benefits with the bivalent AS04-adjuvanted vaccine, from the perspective of public health, for the prevention of cervical cancer and its pre-cancerous lesions

Bonanni

Panatto

Dirodi

et al. 2012

View full text Add to dashboard Cite

show abstract

L’introduzione del vaccino anti-HPV bivalente adiuvato con AS04 nelle regioni italiane: impatto economico ed effetti sulla salute delle donne

Cited by 1 publication

References 7 publications

HPV vaccination and allocative efficiency: regional analysis of the costs and benefits with the bivalent AS04-adjuvanted vaccine, from the perspective of public health, for the prevention of cervical cancer and its pre-cancerous lesions

HPV vaccination and allocative efficiency: regional analysis of the costs and benefits with the bivalent AS04-adjuvanted vaccine, from the perspective of public health, for the prevention of cervical cancer and its pre-cancerous lesions

Contact Info

Product

Resources

About